Get a reply from this employer
Your resume and cover letter, tailored to exactly what they’re hiring for.
Proxima is seeking a Principal ML Performance Engineer to optimize GPU workloads for large-scale models and diffusion-based pipelines. You will profile, tune, and accelerate training and inference on multi-node clusters, with emphasis on memory and kernel efficiency.
Your work drives cost and speed improvements across 32–64 GPUs. You’ll implement custom kernels, use advanced compilers, and collaborate with researchers to push the limits of PyTorch, Triton, and CUDA.
Proxima is a frontier AI and data generation company discovering the next generation of proximity therapeutics by making protein interactions programmable. Our platform brings together foundation-model machine learning, a scalable data generation engine, and a partnership track record exceeding $5B in collaborations across the world’s leading biopharma and tech organizations. We’ve recently closed an oversubscribed seed round with an elite group of VCs including DCVC, NVIDIA’s NVentures, AIX, Yosemite among others.
Neo-1 is our all-atom foundation model that combines state-of-the‑art structure prediction and molecular generation in a single system. Neo-1 enables rapid exploration of chemical and structural space for high value, previously intractable targets, and in particular unlocks small molecule proximity therapeutics like molecular glues with AI for the first time.
In parallel, we are developing an advanced structural interactomics platform built on proprietary XLMS technology and a lab equipped with next‑generation mass spectrometry instrumentation. This platform produces proteome‑scale maps of protein interactions and helps identify small molecules that modulate proximity. Together with Neo‑1, it creates an integrated system capable of co‑folding protein complexes while generating candidate small molecules to influence those interactions.
Proximity‑based therapeutics represent one of the most promising frontiers in modern drug discovery with the potential to treat previously intractable diseases and target ‘undruggable’ proteins. We’re building the tech and the team to make that happen. Come join us!